<DOC>
	<DOCNO>NCT01277497</DOCNO>
	<brief_summary>Chronic kidney disease ( CKD ) patient often high level substance call fibroblast growth factor-23 ( FGF-23 ) , phosphorus excrete hormone , related heart disease . As kidney function decline , less phosphorus remove kidney result phosphorus accumulates blood . In response elevate phosphorus level , FGF-23 release help facilitate excretion extra phosphorus urine . In addition effect FGF-23 , increase phosphorus level lead calcification ( harden ) blood vessel CKD population . Phosphate binding medicine use CKD patient low amount phosphorus absorb stomach intestine eat meal snack . In patient CKD , study show phosphate binder low FGF-23 level blood . Lowering FGF-23 level CKD patient may also lower substance blood cause calcification blood vessel CKD population . This study do determine use phosphate binder , either sevelamer carbonate calcium acetate , early stage kidney disease ( dialysis ) decrease FGF-23 biomarkers ( substance blood ) associate harden blood vessel heart disease .</brief_summary>
	<brief_title>Effect Phosphate Binders Markers Vascular Health Chronic Kidney Disease Stages 3 4</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vascular Calcification</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>Males female â‰¥ 18 year age start screen CKD stage 3 4 define eGFR 15 60 mL/min/1.73m2 Not expect start dialysis 8 month Serum intact PTH &lt; 500 pg/mL screen period On stable ACE inhibitor/ARB regimen 30 day prior screen History follow disease : congestive heart failure , MI within last 6 month , cerebrovascular accident , significant valvular disease , malignancy Currently receive erythropoiesis stimulate agent IV iron therapy History inflammatory/autoimmune disease History polycystic kidney disease HIV positive AIDS Pregnant breastfeed Receiving activate Vitamin D analog , nutritional vitamin D agent &gt; 2,000 IU/day , calcimimetics last 3 month Significant GI disorder Proteinuria &gt; 3.5 g/24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Phosphate binder</keyword>
	<keyword>Sevelamer carbonate</keyword>
	<keyword>Calcium acetate</keyword>
	<keyword>Vascular calcification</keyword>
	<keyword>Endothelial Dysfunction</keyword>
</DOC>